LAB STANDARD BIOTOOLS INC. Insider Trading

Casdin Partners Master Fund, L.P. (Director) purchased 350,000 shares over 3 days (Dec 2-4) at blended avg $1.44, building position to 72.10M shares.

Casdin Partners executed 3 separate purchases totaling 350,000 shares for $502,570.00 across December 2–4, 2025, at prices ranging from $1.42 to $1.45, during a period when LAB stock has rebounded +21.0% over 30 days and +10.8% over 90 days from a 52-week low of $0.92. The transaction occurred in the context of a company with $19.6M quarterly revenue and negative net income of $-34.7M, though annual growth has accelerated +64.0%. Casdin Partners' cross-ticker track record shows strong outcomes (83.33% 90-day win rate, +8.0% avg 90d return on 19 prior buys), but those transactions across other tickers do not yet indicate success at LAB—the 5 prior same-ticker purchases in late November have outcomes not yet measurable. This incremental accumulation (+0.5% vs pre-transaction holdings) suggests continued positioning in LAB after a rapid price recovery, though the unprofitable operating performance and recent timing—well into a 30-day rally—warrant monitoring of near-term fundamentals and execution.

Casdin Partners Master Fund purchases 7,700,000 shares at blended $1.31, raising stake to 71.75M shares in unprofitable LAB

Casdin Partners Master Fund, as a director of Standard Biotools, executed 2 separate purchases totaling 7,700,000 shares for $10,053,280.00 on 2025-11-24 and 2025-11-25, at prices of $1.43 and $1.30 respectively. This acquisition increased the insider's holdings by 12.0% to 71,750,000 shares. The transaction occurs within a context of elevated recent trading activity at LAB—the SAME-TICKER HISTORY shows 5 prior buys in the preceding week (2025-11-14 through 2025-11-20)—suggesting sustained accumulation by this insider. However, the company posted a negative net income of $-34,687,000.00 on quarterly revenue of $19,552,000.00 and remains unprofitable on a full-year basis, despite 64.0% annual revenue growth. The current stock price of $1.43 is 35.3% below the 52-week high, positioning these purchases in a depressed price zone relative to historical range. Investors should focus on whether this concentration of director purchases reflects conviction in a distressed but growing technology platform, or is driven by other factors external to near-term performance signals.

Casdin Partners purchased 925,000 shares across 3 trades (Nov 13–17) at blended $1.22, adding to 62.98M-share position in unprofitable LAB.

Casdin Partners Master Fund, L.P. filed 3 separate purchases totaling 925,000 shares for $1,126,775.00 between November 13–17, 2025, at prices ranging from $1.20 to $1.24 and a blended average of $1.22. The transactions increased the director's holdings by 1.5% to 62,975,000 shares. The current price of $1.21 sits 45.2% below the 52-week high of $2.21 and has declined 4.7% over both the 30- and 90-day periods, placing the purchase in a downtrend. At the same ticker, Casdin has executed 5 prior trades in rapid succession (September 9 through November 12), all purchases, with the earliest showing a modest +5.5% 30-day return but outcomes beyond 30 days not yet measurable. Cross-ticker, Casdin's historical track record shows 16 prior buys with an average 30-day return of +2.0% but an average 90-day return of -10.9% and a 0.00% win rate at the 90-day mark, indicating a pattern of purchases that subsequently underperform. Standard Biotools remains unprofitable ($-34.7M net income on $19.6M quarterly revenue) despite 64% annual revenue growth, a structural condition that may constrain upside and heighten downside risk in a declining market.

Casdin Partners bought 1,175,000 LAB shares over 4 days (Nov 7–12) for $1.4M at blended avg $1.17, expanding stake to 62.05M shares as stock trades 47.1% below 52-week high.

Casdin Partners, a director and substantial shareholder of Standard Biotools, executed 4 separate purchases totaling 1,175,000 (1.18M shares) for $1,379,317.50 ($1.4M) between November 7–12, 2025, at prices ranging from $1.12 to $1.20, slightly below the current market price of $1.18. The blended average price of $1.17 represents purchases into a stock trading 47.1% below its 52-week high and down 8.5% over the prior 30 days. Holdings expanded by 1.9% to 62.05M shares post-transaction. At the same ticker, Casdin's prior 5 buys (August 25–September 9) all showed positive 30-day returns (+4.9% to +5.9%), though none has yet completed a 90-day measurement window. The company remains unprofitable (net income $-34.7M in the most recent full fiscal year) despite annual revenue growth of 64.0%, and current market capitalization stands at $453.8M. This sustained accumulation into a distressed valuation warrants monitoring for whether the outsized revenue growth trajectory supports a recovery from depressed price levels.

Casdin Partners bought 100,000 shares of Standard Biotools at $1.29; stock down -41.2% from 52-week high.

Casdin Partners increased its stake in Standard Biotools by 100,000 shares (100.0K shares) on 2025-09-09 at $1.29, part of a series of five purchases since 2025-08-22. The stock trades at $1.33, down -41.2% from its 52-week high of $2.26, though up +26.7% over the past 90 days. Standard Biotools reported revenue of $21,762,000.00 with net income of $-33,459,000.00 in its latest quarter and remains unprofitable on an annual basis, despite showing +64.0% annual revenue growth. The insider's own cross-ticker track record shows a 90-day win rate of just 11.11% on buys, with prior purchases averaging -13.4% 90-day returns. No measurable outcome exists yet for the five recent purchases at this ticker.

Casdin Partners bought 500,000 shares (500.0K) at avg $1.27, raising stake to 60.78M; stock up 22.6% in 90d but deeply unprofitable.

Casdin Partners Master Fund made two separate purchases totaling 500,000 shares for $635,750.00 on consecutive days (2025-09-03 and 2025-09-04) at an average blended price of $1.27, increasing holdings from 60.28M to 60.78M shares. The stock has appreciated 22.6% over the prior 90 days and trades at $1.30, well above the transaction prices, suggesting the purchases were made into a rallying period. However, Standard BioTools remains deeply unprofitable with a net loss of $33,459,000.00 against quarterly revenue of $21,762,000.00, despite 64.0% annual revenue growth. Casdin's five prior purchases at this ticker (all within the prior two weeks in August 2025) signal sustained accumulation, but outcomes are not yet measurable. The cross-ticker track record shows a 27.27% win rate on buys at the 90-day horizon—a notably poor success rate—suggesting caution about relying on historical timing patterns to predict this position's performance.

Director fund purchased 525,000 shares at $1.25 avg (Aug 22–26) amid -42.9% drawdown from 52-week high

Casdin Partners Master Fund, L.P., a director at Standard Biotools, executed 3 separate purchases totaling 525,000 shares for $658,797.50 between August 22–26, 2025, at prices ranging from $1.24 to $1.26. The current price of $1.29 sits -42.9% below the 52-week high of $2.26 and has declined -7.9% over the past 30 days, suggesting the company faces near-term headwinds. At the same-ticker level, Casdin's prior two measurable outcomes showed mixed results: a +7.0% 30-day return on a February 2025 buy but a -25.9% 90-day return on an August 2024 buy, indicating inconsistent timing on prior LAB purchases. The company reported a net loss of $33,459,000.00 on quarterly revenue of $21,762,000.00, though full-year revenue growth reached +64.0%, showing execution challenges in profitability despite top-line expansion. The concentration of three buys in consecutive trading days during a depressed price window merits investor scrutiny of whether the fundamental picture has stabilized or whether the timing reflects exogenous factors rather than conviction tied to operational recovery.

Casdin Partners Master Fund bought 358,220 shares over 3 days (Aug 13-15) at $1.24 average, adding 0.6% to its 59.75M position in unprofitable LAB.

Casdin Partners Master Fund made 3 separate purchases totaling 358,220 shares for $443,032.57 between August 13–15, 2025, at prices ranging from $1.21 to $1.31 per share. The timing coincides with LAB trading near 52-week lows (-45.6% from the $2.26 peak), though the stock has recovered +13.9% over the 90-day period. However, Casdin's prior trades at LAB exhibit a consistent pattern: 0 of 5 prior buys were well-timed at the 90-day mark, with post-purchase returns ranging from -25.9% to +7.0% over three months. The company remains unprofitable (net income of $-33.5M against $21.8M quarterly revenue) despite strong annual revenue growth of +64.0%. The accumulation is modest relative to Casdin's existing 59.75M-share stake, raising the question of whether this represents deliberate re-engagement with a struggling name or a small portfolio adjustment.

Casdin Partners bought 4.82M LAB shares at $1.06; stock down 63.7% from 52-week high, all prior LAB buys showed negative 90d returns.

Casdin Partners, a director, purchased 4,820,959 shares of Standard BioTools at $1.06 on 2025-02-28, increasing holdings to 2,806,470 shares post-transaction. The stock is trading at $1.06, down 63.7% from its 52-week high of $2.92 and down 31.6% over the past 30 days. Critically, Casdin's prior trades at LAB show a troubling pattern: all 5 prior purchases at this ticker resulted in negative 90-day returns (ranging from -17.8% to -25.9%), with zero prior buys proving well-timed at the 90-day mark. The company itself is unprofitable, reporting net income of -$26,938,000 on quarterly revenue of $44,969,000. This large purchase into a deeply depressed stock with a documented track record of poor timing outcomes at the same ticker merits investor attention, particularly given the fundamental weakness and continued downward momentum.

Casdin Partners (Director) bought 250,000 shares of LAB at $2.19 on 2024-08-27; stock now $2.08, down -31.8% from 52-week high.

Casdin Partners purchased 250,000 shares at $2.19 on 2024-08-27, one day after another buy of 30,000 shares at the same ticker, as part of a pattern of five consecutive daily buys between 2024-08-20 and 2024-08-27. The stock has since declined to $2.08, down -31.8% from its 52-week high of $3.05. Casdin's cross-ticker track record shows 20 prior buys with an average 90-day return of -29.8% and a 0.00% win rate, indicating a consistent pattern of poorly-timed purchases. Standard Biotools generated $37.2M in quarterly revenue but posted a $-45.7M net loss in the most recent period, with the company remaining unprofitable on a full-year basis. The repeated daily accumulation at a declining stock price by an insider with a demonstrably unfavorable cross-ticker trading record, combined with the company's ongoing losses, presents a cautionary signal rather than a confidence indicator.